

# Practice Guideline



## AASLD IDSA Practice Guideline on treatment of chronic hepatitis B

### Abstract

**Background and Aims:** Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.

**Methods:** The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline.

**Conclusions:** This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.

**Keywords:** antiviral discontinuation, grey zone, hepatocellular carcinoma, horizontal transmission, immune-tolerant, indeterminate, pregnancy, surveillance

### CORE CONCEPTS REGARDING CHRONIC HEPATITIS B (CHB)

- Chronic hepatitis B (CHB) is a dynamic disease that can be characterized into five phases (Table 1): **immune-tolerant** (hepatitis B e antigen [HBeAg]-positive, HBV DNA  $\geq 10,000,000$  IU/mL and normal alanine

Marc G. Ghany<sup>1</sup>   
 Calvin Q. Pan<sup>2</sup>   
 Anna S. Lok<sup>3</sup>   
 Jordan J. Feld<sup>4</sup>   
 Joseph K. Lim<sup>5</sup>   
 Su H. Wang<sup>6,7,8</sup>   
 Arthur Y. Kim<sup>9,10</sup>   
 Amy S. Tang<sup>11</sup>   
 Mindie H. Nguyen<sup>12,13,14</sup>   
 Susanna Naggie<sup>15</sup>   
 Mark S. Sulkowski<sup>16</sup>   
 Norberto Rodriguez-Baez<sup>17</sup>   
 Jacki Chen<sup>18,19</sup>   
 M. Hassan Murad<sup>20,21</sup>   
 Khaled S. Mohammad<sup>21,22</sup>   
 Norah A. Terrault<sup>23</sup>

<sup>1</sup>Clinical Hepatology Research Section, Liver Diseases Branch, National Institute of Diabetes and Digestive Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

<sup>2</sup>Division of Gastroenterology and Hepatology, NYU Langone Health, New York University Grossman School of Medicine, New York, NY, USA

<sup>3</sup>Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

<sup>4</sup>Toronto Centre for Liver Disease, University Health Network, Canada

<sup>5</sup>Section of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, New Haven, CT, USA

<sup>6</sup>Center for Asian Health at Cooperman Barnabas Medical Center, Florham Park, NJ, USA

<sup>7</sup>Rutgers New Jersey Medical School, Newark, NJ, USA

<sup>8</sup>Rutgers Institute for Health, Health Care Policy and Aging Research (IFH), New Brunswick, NJ, USA

**Abbreviation:** AASLD, American Association for the Study of Liver Diseases; anti-Hbs, antibody to HBsAg; ALT, alanine aminotransferase; CDC, Centers for Disease Control and Prevention; CI, confidence interval; CHB, chronic hepatitis B; DAA, direct acting antiviral; EtD, evidence to decision; ETV, entecavir; GRADE, Grading of Recommendation Assessment, Development and Evaluation; HBIG, hepatitis B immune globulin; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HBcrAg, hepatitis B core-related antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; MTCT, mother-to-child transmission; NA, nucleos(t)ide analogue; PICO, Population, Intervention Comparison, Outcomes; SHEA, Society for Healthcare Epidemiology of America; TAF, tenofovir alafenamide; TBD, to be determined; TDF, tenofovir disoproxil fumarate; ULN, upper limit of normal; U.S., United States; USPSTF, U.S. Preventive Services Task Force; WHO, World Health Organization.

Copyright © 2025 American Association for the Study of Liver Diseases.

<sup>9</sup>Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

<sup>10</sup>Department of Medicine, Harvard Medical School, Boston, MA, USA

<sup>11</sup>North East Medical Services, San Francisco, CA, USA

<sup>12</sup>Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA

<sup>13</sup>Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA, USA

<sup>14</sup>Stanford Cancer Institute, Stanford University Medical Center, Palo Alto, CA, USA

<sup>15</sup>Department of Medicine, Duke University School of Medicine, Durham, NC, USA

<sup>16</sup>Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA

<sup>17</sup>Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, USA

<sup>18</sup>Taiwan Hepatitis Information & Care Association (THICA), Princeton, NJ, USA

<sup>19</sup>Rutgers Health, Robert Wood Johnson Medical School, Piscataway, NJ, USA

<sup>20</sup>Mayo Clinic Evidence-based Practice Center, Mayo Clinic, Rochester, MN, USA

<sup>21</sup>Preventive Medicine, Mayo Clinic, Rochester, MN, USA

<sup>22</sup>Division of Community Pediatric and Adolescent Medicine, Mayo Clinic Children's, Rochester, MN, USA

<sup>23</sup>Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

#### Correspondence

Marc G. Ghany, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 10, Room 9B-16, 10 Center Drive, MSC 1800, Bethesda, MD 20892.

Email: [marcg@intra.niddk.nih.gov](mailto:marcg@intra.niddk.nih.gov)

Norah A. Terrault, Division of GI and Liver Disease, Keck School Of Medicine, University of Southern California, 1450 San Pablo Street, HC4 3000, Los Angeles, CA, 90033.

Email: [norah.terrault@med.usc.edu](mailto:norah.terrault@med.usc.edu)

aminotransferase (ALT) defined as <35 U/L for males and <25 U/L for females); **HBeAg-positive immune active** (HBeAg-positive, ALT  $\geq$  2x upper limit of normal (ULN) and HBV DNA  $\geq$  20,000 IU/mL); **HBeAg-negative immune active** (HBeAg-negative, ALT elevated  $\geq$  2x ULN and and HBV DNA  $\geq$  2000 IU/mL); **inactive** (HBeAg-negative, normal ALT and HBV DNA <2000 IU/mL); and **hepatitis B surface antigen (HBsAg)-negative immune clearance** (HBV DNA undetectable,  $\pm$  antibody to HBsAg (anti-HBs)).<sup>[1]</sup> As persons transition across phases over the lifetime of their infection, regular monitoring is essential to identify when a change of management is indicated, including use of antiviral therapy.

- **Indeterminate phases** refer to persons who are HBsAg-positive, HBeAg-positive or negative and have ALT and HBV DNA levels that do not meet the thresholds for immune active phase and are outside the thresholds defining immune tolerant or inactive CHB (Table 1). Up to 40% of adults with CHB do not meet one or more criteria for a defined phase and are

in indeterminate phases.<sup>[2,3]</sup> Indeterminate phases are more common in persons who are HBeAg-negative than HBeAg-positive.<sup>[2-4]</sup> An alternative term used to refer to these phases is “grey zone”.

- Determination of liver disease severity is integral to monitoring because of its importance to making treatment and surveillance decisions. Non-invasive tests of fibrosis, such as hepatic transient elastography or serum markers such as FIB-4 can be considered for fibrosis staging, with elastography generally showing better performance than FIB-4.<sup>[5,6]</sup> Liver biopsy is infrequently used but is the most accurate means of defining severity of inflammation.<sup>[7]</sup>
- Two classes of drugs are approved for the treatment of CHB: peginterferon and nucleos(t)ide analogues (NAs). Peginterferon is rarely used, given its limitations of applicability, safety and tolerability, compared with NA therapy. There are three NAs that are preferred for treatment of CHB: entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF). All 3 drugs provide high efficacy in achieving HBV DNA suppression, have low rates of antiviral resistance, and are well tolerated and broadly applicable (including for persons with decompensated cirrhosis and immunocompromised states). Selecting among these drugs is based upon availability/cost, age, presence of renal or bone disease (avoid TDF), pregnancy (avoid ETV), HIV coinfection (avoid ETV unless HIV RNA suppressed on antiretroviral regimen), and prior treatment history (avoid ETV if prior lamivudine exposure). All drugs require consideration of renal function and/or dialysis. TAF is not recommended if creatinine clearance is less than 15mL/min and not yet on dialysis. ETV and TDF need dose adjustment if renal dysfunction or on dialysis, though a change in NA is preferred for those on TDF with declining renal function.
- The goals of antiviral treatment are prevention of progression to cirrhosis, development of hepatocellular carcinoma (HCC) and liver-related death. These clinical endpoints typically take years or decades to develop. Therefore, surrogate virological (HBV DNA undetectable by a PCR-based assay, HBeAg loss and seroconversion, HBsAg loss and seroconversion), biochemical (serum ALT normal) and infrequently, histological (improvement in necroinflammation by  $\geq$  2 points with no worsening of fibrosis) endpoints are used as measures of treatment efficacy.
- Other goals of antiviral therapy include reduction in onward transmission (both vertical (mother-to-child) and horizontal (e.g., sexual, parenteral, nosocomial)), improvement in patient reported outcomes and quality of life as well as decreased stigma.
- Increasingly, there is emphasis on the achievement of HBsAg loss as the desired endpoint for treatment (functional cure), because of its association with reduction in clinical outcomes and long-term

**TABLE 1** Definitions and terms**Phases of CHB**

Immune-tolerant CHB	HBeAg-positive, HBV DNA $\geq 10,000,000$ IU/mL and normal ALT ( $< 25$ IU/mL in women, $< 35$ IU/mL in men)
Immune active CHB	HBeAg-positive and ALT $\geq 2 \times$ ULN and HBV DNA $\geq 20,000$ IU/mL HBeAg-negative and ALT $\geq 2 \times$ ULN and HBV DNA $\geq 2000$ IU/mL
Inactive CHB	HBeAg-negative, HBV DNA $< 2000$ IU/mL and normal ALT
Indeterminate CHB	HBeAg-positive or negative with HBV DNA level and/or ALT level outside those with immune-tolerant, immune active or inactive CHB (Figures 1 and 2). An alternative term used to refer to this group is "grey zone"
HBsAg loss	Loss of HBsAg on antiviral therapy or spontaneously in person who was previously HBsAg-positive

**Key Terms**

Functional cure	HBsAg-negative and HBV DNA undetectable off treatment for at least 6 mo ( $\pm$ anti-HBs)
Partial cure	HBsAg $< 100$ IU/mL with HBV DNA undetectable off treatment for at least 6 mo

durability, though it is recognized that functional cure is infrequent with current approved therapies, albeit higher with peginterferon than for NAs.

- Shared decision making is a collaborative process where a healthcare provider and patient make informed healthcare decisions by considering clinical evidence, taking into account the individual's personal values, preferences, and circumstances, allowing the patient to actively participate in choosing the best treatment option for them.

## INTRODUCTION/BACKGROUND

CHB affects ~258 million individuals (2022) globally<sup>[8]</sup> and leads to an estimated 1.1 million deaths annually due to complications of cirrhosis and HCC. Data from the National Health and Nutrition Examination Survey (2017-2020) identified an estimated 660,000 (Confidence Interval (CI): 410,000–1,000,000) persons with HBV infection<sup>[9]</sup> but with adjustments for infections among foreign-born persons immigrating to the United States (U.S.), the estimated disease burden of HBV infection may be as high as 1.8 million (C.I.: 1.3–2.6 million).<sup>[10]</sup> Importantly, half of those infected are unaware of their diagnosis.<sup>[9]</sup> To reduce the morbidity and mortality of CHB, there is a need for continued efforts to identify infected individuals, prevent new infections through vaccination, initiate timely treatment with antiviral therapy and monitor for complications including surveillance for HCC. Consequently, the Centers for Disease Control and Prevention (CDC) recommends screening for hepatitis B in all adults aged  $\geq 18$  years at least once during a lifetime and all pregnant persons during each pregnancy, preferably in the first trimester, regardless of vaccination status or history of testing using a triple panel, (HBsAg, anti-HBs, and total anti-HBc). HBV vaccination is recommended for all infants, all children and adolescents younger than 19 who have not been vaccinated, all adults aged 19-59 years regardless of risk factors and adults aged 60 years and older with risk

factors for HBV or without known risk factors but who desire protection.

Antiviral therapy has been traditionally prioritized for persons at greatest risk for disease progression or development of HCC. These include those with immune active disease, as indicated by elevated ALT and hepatitis B virus (HBV) DNA levels and/or presence of significant liver inflammation or fibrosis. Treatment of these individuals has been shown to reduce the incidence of progression to cirrhosis, development of HCC, need for liver transplantation and HBV-related liver mortality.<sup>[11–13]</sup> Given the safety and excellent tolerability of NA therapy and the current gaps in HBV care and treatment,<sup>[11,12]</sup> the World Health Organization (WHO) has recommended a simplification and expansion of antiviral treatment criteria,<sup>[13]</sup> in part to address the high disease burden in low and middle-income countries.

This guideline focuses on six specific issues related to management of CHB. Other recommendations for management of CHB addressed in the 2018 guidelines will continue to be applicable and the reader is referred to this document.<sup>[1]</sup> As this guideline is focused primarily on treatment, topics related to the screening and diagnosis of CHB were not included. The key questions addressed in this guideline are those commonly faced by providers in daily practice:

1. What is the optimal antiviral strategy for HBsAg-positive pregnant individuals with HBV DNA  $> 200,000$  IU/mL to prevent mother-to-child transmission (MTCT) of HBV?
2. Should antiviral therapy be provided to persons who are HBsAg-positive with viremia that do not meet disease-specific treatment indications to reduce transmission in high-risk scenarios?
3. Should HBsAg-positive individuals in the immune-tolerant phase start antiviral therapy versus observation?
4. Should HBsAg-positive, HBeAg-negative individuals without cirrhosis and in the indeterminate phase start antiviral therapy versus observation?

5. Should HBsAg-positive individuals without cirrhosis who have been on nucleos(t)ide analogue therapy for at least 3 years and who are HBeAg-negative with undetectable HBV DNA remain on or discontinue therapy?
6. Should individuals with chronic HBV without cirrhosis who clear HBsAg and HBsAg-positive persons with hepatitis C virus (HCV), hepatitis D virus (HDV), and/or human immunodeficiency virus (HIV) co-infection receive surveillance for HCC?

This guideline is intended primarily for health care professionals caring for those with CHB. Additionally, this guideline may assist policy makers in optimizing the care of individuals living with CHB. As with any clinical practice guideline, it provides general guidance to optimize the care of most individuals with CHB, but this should not replace clinical judgement where clinical considerations may justify a course of action that differs from this guideline. A shared decision-making approach between patient and provider is strongly endorsed.

## METHODS

### Overview

This guideline was developed in compliance with the National Academy of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of this guideline will be obtained by reading the applicable portions of the systematic reviews.

### Formulation of clinical questions and determining outcomes of interest

The methodology team from the Mayo Clinic Evidence-based Practice Center facilitated brainstorming sessions in which the panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel prioritized 6 questions. The panel also ranked the outcomes of interest to prioritize patient-important outcomes.

### Review of evidence

Existing systematic reviews were identified to address 2 of the 6 PICO questions. *De novo* systematic reviews were conducted for 4 PICO questions. A comprehensive search of several databases was conducted from

each database's inception to February 13, 2024, (questions 1-3) and December 5th, 2024 (question 4). Databases included MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by an experienced librarian with input from the methodology team. Controlled vocabulary and keywords were used to describe search concepts. Details of the systematic reviews, inclusion and exclusion criteria, risk of bias assessment and synthesis methods are detailed in the accompanying technical review.<sup>[14]</sup>

### Development of recommendations

This guideline follows the GRADE approach.<sup>[15]</sup> The approach starts with determining certainty in the evidence (i.e., how trustworthy are the estimates of effect). Certainty can be high, moderate, low or very low. Randomized trials start by warranting high certainty and nonrandomized studies low certainty. Certainty can then be rated down due to risk of bias, imprecision, inconsistency, indirectness or publication bias. Certainty can be rated up due to large effects, dose-response gradients and based on the direction of plausible confounding.<sup>[16]</sup> The second step of GRADE is to apply the evidence to decision (EtD) framework to balance the desirable and undesirable effects and consider contextual factors such as patient values, resource use, feasibility, acceptability and equity.<sup>[17]</sup> Recommendations can be strong or conditional based on the judgments of the EtD criteria. A majority vote by the panel determined the direction and strength of the recommendations.

### Interpretation of strong and conditional recommendations

A strong recommendation is made when guideline developers believe that all or almost all informed people would make the recommended choice for or against an intervention. A conditional recommendation is made when guideline developers believe most informed people would choose the recommended course of action, but a substantial number would not. A strong recommendation implies uniformity and the need to facilitate implementation, whereas a conditional recommendation means that the focus of providers and patients should be on shared-decision-making and eliciting values and preferences. For policymakers, the implication of a strong recommendation is that the recommendation can be adopted as a policy in most situations because variability in clinical practice would likely be inappropriate. Conversely, a conditional recommendation implies that variability between individuals or regions may be appropriate.<sup>[18]</sup>

**PICO Question 1: What is the optimal antiviral strategy for HBsAg-positive pregnant individuals with HBV DNA > 200,000 IU/mL to prevent mother-to-child transmission (MTCT) of HBV?**

**Population:** HBsAg-positive pregnant individuals with HBV DNA levels > 200,000 IU/mL

**Intervention:** Maternal antiviral therapy with TDF or TAF

**Comparator:** TDF versus no antiviral intervention, or TDF versus TAF during pregnancy

**Outcome:** (a) MTCT if the infants receive standard immunoprophylaxis and (b) antiviral safety

**Recommendation:**

1. For pregnant persons with HBV DNA levels greater than 200,000 IU/mL at any time point during pregnancy, regardless of HBeAg status, AASLD recommends initiating tenofovir disoproxil fumarate or tenofovir alafenamide at gestational week 28 to prevent mother-to-child transmission. Tenofovir disoproxil fumarate has a more extensive safety record in pregnancy than tenofovir alafenamide.

*Strength of recommendation: Strong  
Certainty of evidence: Moderate*

### Implementation considerations

- For pregnant persons who have been receiving HBV treatment with TDF or TAF, we suggest continuing therapy. For those receiving entecavir or other antivirals, we suggest switching to TDF or TAF, given their established efficacy and safety in pregnancy.
- Amniocentesis increases the risk of perinatal transmission in those with HBV DNA > 2,000,000 IU/mL. Therefore, initiating TDF or TAF early in pregnancy to achieve viral suppression should be considered when invasive procedures are anticipated. Similarly, if the pregnant individual has a high risk for preterm labor, earlier TDF or TAF treatment should be considered.
- The optimal timing of initiation of TDF/TAF prophylaxis is at gestational week 28. For mothers with HBV DNA levels > 200,000 IU/mL who seek perinatal care later than week 28, TDF or TAF prophylaxis should still be initiated immediately to reduce the risk of MTCT.
- For mothers with HBV DNA levels > 200,000 IU/mL, TDF or TAF prophylaxis should be initiated at gestational week 16 in combination with subsequent infant vaccination, if hepatitis B immune globulin (HBIG) use in the infant is unavailable.
- For pregnant persons for whom the sole purpose of treatment is to prevent perinatal transmission, we suggest TDF or TAF can be discontinued at delivery.

- For pregnant persons in whom treatment is discontinued, we suggest HBV DNA and ALT should be monitored for withdrawal flares at intervals of 1-3 months for a period of up to six months. Treatment should be reinitiated in the event of a significant withdrawal flare (ALT  $\geq$  5 x upper limit of normal).
- For breastfeeding persons who require or are on HBV treatment, we suggest the use of TDF or TAF.

### Background

Screening for HBV infection in all pregnant persons during their initial prenatal visit, for every pregnancy, using a triple panel (HBsAg, anti-HBs and total anti-HBc) is strongly recommended by the CDC and U.S. Preventive Services Task Force guidelines (USPSTF).<sup>[19,20]</sup> A positive HBsAg result should be followed by quantitative HBV DNA, HBeAg, and ALT testing to determine the risk of perinatal transmission and to assess the severity of maternal liver disease.<sup>[21-23]</sup> Non-invasive tests for fibrosis may not be reliable during pregnancy;<sup>[5]</sup> however, assessment for cirrhosis using ultrasound and/or clinical evaluation is important, as it could alter management.

Despite the appropriate administration of hepatitis B immune globulin (HBIG) and birth-dose vaccination within 24 hours of birth,<sup>[23]</sup> perinatal transmission of HBV occurs in approximately 8–10% of infants born to HBsAg-positive pregnant persons with HBV DNA levels > 200,000 IU/mL.<sup>[21,23]</sup> The 2018 AASLD conditional recommendations for these individuals included initiating TDF therapy (preferred) at gestational weeks 28–32, continuing until delivery or up to three months postpartum.<sup>[1]</sup> Interim data from clinical trials have provided additional safety data on TAF as well as the timing of antiviral prophylaxis initiation and discontinuation for pregnant persons whose only indication for antiviral therapy is the prevention of MTCT.<sup>[24]</sup>

### Evidence and rationale

Prophylactic TDF therapy, initiated from the start of the third trimester (gestational week 28 onwards) until delivery, among pregnant persons with high viremia (> 200,000 IU/mL) effectively reduces maternal viremia and decreases the rate of MTCT.<sup>[21,24-26]</sup> A systematic review evaluating the efficacy and safety of TDF versus TAF in preventing MTCT included 31 studies: 2,588 highly viremic pregnant individuals received TDF, 280 received TAF, and 1,600 received no treatment. Compared to no treatment, TDF and TAF were equally effective (risk ratio: 1.09, 95% CI 0.15–7.65) and safe (risk ratio 1.11 (95% CI 0.5–2.5 for TDF)).<sup>[24]</sup> TDF or TAF are preferred over lamivudine due to their lower risk of antiviral resistance<sup>[21,27]</sup> and established long-term safety

data in infants of HBV-infected and/or HIV-infected pregnant persons.<sup>[24,25,28]</sup> There are insufficient safety data to recommend ETV use during pregnancy.<sup>[21,28]</sup>

In the absence of birth-dose HBIG, the rate of MTCT of HBV among untreated HBeAg-positive persons is 16–25%. A recent RCT found that starting TDF at gestational week 16 with infants HBV vaccination was noninferior to starting TDF at week 28 with HBIG and vaccination in preventing transmission in pregnant individuals with HBV DNA > 200,000 IU/mL (0.76% [1/131] vs. 0% [0/142]). Thus, TDF initiation at week 16 should be considered for viremia control with subsequent infant HBV vaccination if HBIG is not an option for the infant.<sup>[29]</sup> Amniocentesis increases the risk of perinatal transmission in those with HBV DNA > 2,000,000 IU/mL.<sup>[30]</sup>

Post-delivery, the continuation of antiviral therapy should be guided by maternal CHB treatment needs through shared decision-making, considering clinical factors, maternal values and preferences, as well as future conception plans (Figure 1). Discontinuing TDF or TAF prophylaxis post-delivery is appropriate if continued antiviral treatment is not necessary. The risks of ALT flares are comparable regardless of TDF cessation at delivery versus at postpartum weeks 4–12.<sup>[24]</sup> Close monitoring with HBV DNA and ALT every 1–3 months for up to six months after discontinuation is suggested, with the potential reintroduction of antiviral therapy warranted for significant hepatitis flares (defined as ALT  $\geq$  5x ULN).<sup>[23,25]</sup> Breastfeeding does not increase HBV transmission risk, and TDF or TAF use during lactation is safe for both the mother and the infant.<sup>[31–34]</sup>

**PICO Question 2: Should antiviral therapy be provided to persons who are HBsAg-positive with viremia that do not meet disease-specific treatment indications to reduce transmission in high-risk scenarios?**

**Population:** HBsAg-positive persons in high-risk settings to transmit to HBsAg-negative persons

**Intervention:** Use of antiviral therapy

**Comparator:** No use of antiviral therapy

**Outcomes:** (a) New HBV infection in an exposed uninfected individual (HBsAg negative person tests HBsAg positive); (b) Safety of antivirals

#### **Recommendation 2:**


For persons who are HBsAg-positive with viremia not meeting disease-specific treatment indications and who are in high-risk scenarios for transmission to others, AASLD suggests a shared decision-making approach regarding antiviral treatment.

*Strength of recommendation: Conditional*

*Certainty of evidence: Very Low*

## Implementation considerations

- Individuals who are viremic and in high-risk scenarios for transmission may be offered antiviral treatment to reduce risk of transmission, though there are limited data on this issue. Shared decision-making is critical to evaluate exposure and transmission risk and to consider the vaccine and immunity status of those who are potentially exposed, favoring antiviral treatment if the person at risk for acquiring HBV is unvaccinated, had an inadequate response to vaccine, have compromised immune systems, and/or have unknown vaccine status (Table 2). As risks may not always be disclosed, individuals requesting treatment for prevention of transmission can be prescribed antiviral medication.
- It is essential to avoid stigmatizing practices or messages in discussions regarding horizontal transmission. People with CHB should not be restricted in their daily activities, contact sports, school activities, professional training, and should not be required to take antivirals due to risk of transmission in those settings. Within households, worksites, and other settings, routine contact, sharing meals, and hugging are not considered routes of transmission, though sharing of personal hygiene items (e.g., toothbrush, razor) should be avoided.
- Most healthcare workers with CHB are not in high-risk scenarios to transmit HBV to their patients, but healthcare workers performing Society for Healthcare Epidemiology of America (SHEA) category III exposure-prone procedures are at higher risk for HBV transmission and should follow guidelines from SHEA and the CDC and may require antiviral treatment to reduce transmission risk.<sup>[36,37]</sup> Both CDC and SHEA recommend against the need for healthcare worker disclosure to patients and staff. CHB is a protected condition by the American with Disabilities Act and people with CHB are protected from discrimination in employment, education and other areas, and all cases of discrimination should be reported to appropriate authorities.
- All persons considering or initiating antiviral therapy for prevention of HBV transmission should be counseled regarding the risks of treatment cessation. If the primary indication is the reduction of horizontal transmission risk, the continuation of antiviral therapy may be revisited when transmission risks are no longer high. Examples include healthcare workers no longer engaged in category III/exposure-prone procedures and those for whom the risk of transmission has decreased via harm reduction and/or immunization of susceptible persons. The decision to continue or stop antiviral therapy should be guided by shared decision-making, considering clinical factors, personal values and preferences, and potential risks of post-cessation ALT flare.



**FIGURE 1** Management algorithm for pregnant persons with chronic hepatitis B infection. For persons who are found to be HBsAg-positive and not on antiviral therapy, HBV DNA should be assessed. Those with HBV DNA levels  $> 200,000$  IU/mL should initiate antiviral therapy with TDF or TAF, preferably at gestational week 28 or any time prior to delivery. Antiviral therapy can be discontinued at delivery if there is no ongoing indication for treatment other than preventing perinatal transmission. If treatment is discontinued, HBV DNA and ALT should be monitored at intervals of 1-3 months for a period of up to six months for withdrawal flares. Treatment should be reinitiated in the event of a significant flare ( $ALT \geq 5 \times$  upper limit of normal). Persons who are known to be HBsAg-positive and receiving antiviral therapy should continue antiviral therapy throughout pregnancy and after delivery. Persons receiving ETV should switch to TDF or TAF during pregnancy and breastfeeding. Breastfeeding is safe while taking TDF or TAF. Infants born to HBsAg-positive women should receive hepatitis B immune globulin and first dose of HBV vaccine within 12 hours of birth. They should complete the HBV vaccine schedule based on birth weight. Testing for HBsAg and anti-HBs should occur at 9-12 months of age. Abbreviations: CHB, chronic hepatitis B; ETV, Entecavir; HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; MTCT, mother-to-child transmission; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide; ULN, upper limit of normal.

## Background

Vaccination of susceptible persons, universal precautions, harm reduction strategies to reduce transmission by injection drug use (e.g., needle exchange programs), and barrier methods during sex are mainstays of

preventing horizontal transmission of HBV. Despite recommendations for HBV vaccination in the U.S., including more recently universal vaccination of all persons 59 years of age or younger,<sup>[38]</sup> many individuals are susceptible to acquiring HBV infection (anti-HBc and anti-HBs negative) due to missed HBV

**TABLE 2** Implementation considerations for persons who are HBsAg positive and viremic, do not meet disease-specific treatment indications and are in high-risk scenarios for transmission.

**Non-pharmacologic measures are the mainstay of HBV prevention**

- HBV vaccination is the primary intervention to prevent HBV transmission to susceptible individuals in all settings, including those with a known higher risk of exposure.
- Screening for HBV infection in all people, including those potentially exposed to an individual who is HBsAg positive with viremia, household contacts and sex partners, is strongly recommended by the CDC and U.S. Preventive Services Task Force guidelines.<sup>[19,20]</sup>
- Other important risk mitigators include universal precautions in healthcare and first aid settings, harm reduction, and barrier methods during sex.

**Considerations for antiviral treatment for the main purpose to prevent onward transmission**

- HBV treatment to prevent onward transmission is not necessary for average risk scenarios for transmission<sup>a</sup>
- Possible high-risk scenarios for horizontal transmission of HBV include persons who are engaging in unprotected sex or with multiple partners, persons who are injecting drugs with inconsistent harm reduction practices, persons living with susceptible household members and healthcare workers performing Society for Healthcare Epidemiology of America (SHEA) level III exposure-prone procedures
- Utilize a shared decision-making approach to assess overall horizontal transmission risk and the individual's values and preferences regarding this risk and that of taking antivirals with the primary goal of preventing transmission to others
- Decisions are influenced by the individual's hepatitis B viremia, the exposure scenario and the vaccine and immunity status of those who are potentially exposed. Situations favoring antiviral treatment of the viremic person include those where the person at risk for acquiring HBV is unvaccinated, has inadequate response to vaccine and/or has compromised immune systems,<sup>b</sup> or has unknown vaccine status.
- Providers should avoid stigmatizing practices and messages
- Once initiated for the prevention of HBV transmission, antiviral therapy should be continued until the high risk of transmission is no longer present
- People starting antiviral therapy should be counseled regarding the risks of treatment cessation, which may include severe ALT flares (see sections on MTCT and nucleos(t)ide analog withdrawal)
- Though there are no definitive studies on the lowest level of viral load transmissibility,<sup>c</sup> the goal of HBV treatment is HBV DNA suppression to less than the lower limit of quantification

<sup>a</sup>HBV is not transmitted from casual contact, and people with hepatitis B should not be restricted in their daily activities, contact sports, school activities or professional training, and should not be required to be treated in those settings. Within households, worksites, and other settings, it is important to emphasize that routine contact, sharing meals, hugging are not considered routes of transmission, though sharing of personal hygiene items (e.g. toothbrush, razors) should be avoided.<sup>[13]</sup>

<sup>b</sup>Groups known to have inadequate response to vaccine include persons with immunocompromising conditions, persons with diabetes, persons with advanced liver disease, persons with advanced kidney disease, persons who smoke and obese individuals.<sup>[35]</sup>

<sup>c</sup>For health care providers performing Category III procedures, the Society for Healthcare Epidemiology of America (SHEA) guidelines suggest maintaining HBV DNA < 1000 IU/mL<sup>[36]</sup> (see reference for SHEA Category III procedures and recommendations).

See Appendix

Abbreviations: CDC, Centers for Disease Control and Prevention; HBV, hepatitis B virus; MTCT, mother-to-child transmission; SHEA, Society for Healthcare Epidemiology of America; U.S., United States.

vaccination opportunity or insufficient response.<sup>[39]</sup> In the U.S., the number of people with acute HBV infection remains high, with an estimated 13,000 or more cases in 2022.<sup>[37]</sup>

People who are HBsAg positive but do not meet disease-specific treatment indications may be in high-risk settings where horizontal transmission of HBV to susceptible persons may occur (Table 2). Possible high-risk scenarios for horizontal transmission of HBV include persons who are engaging in unprotected sex or with multiple partners, persons who are injecting drugs with inconsistent harm reduction practices, persons living with susceptible household members and healthcare workers performing level III exposure-prone procedures.<sup>[40]</sup> Extrapolating from more robust data regarding the prevention of vertical transmission from

mother to child,<sup>[21]</sup> a systematic review was conducted to investigate if antiviral treatment may prevent horizontal transmission.<sup>[14]</sup> SHEA and other committees worldwide have established guidance for managing healthcare workers engaged in category III/exposure-prone procedures with variable HBV DNA thresholds allowed.<sup>[40,41]</sup> Antiviral therapy is recommended in these scenarios to suppress HBV DNA below specific thresholds despite a paucity of data indicating such strategies' effectiveness.

## Evidence and rationale

Indirect evidence from a few nonrandomized studies suggests that use of antiretroviral regimens with activity

against HBV may prevent de-novo HBV infection among unvaccinated HIV positive individuals engaged in high-risk behavior.<sup>[42–45]</sup> Additionally, there are no reported transmissions in the literature from healthcare workers with low or undetectable HBV DNA while on therapy to their patients.<sup>[36,37]</sup> While the absence of reports does not completely exclude the possibility of transmission from people with suppressed HBV DNA, there is biological plausibility that lowering HBV DNA with antiviral therapy reduces the risk of horizontal transmission. There is high acceptability, especially for those concerned about transmission including healthcare workers, due to ethical responsibilities to avoid harm to others. Due to biological plausibility, high acceptability, and lack of significant harm, for people who are HBsAg positive with viremia but do not meet disease-specific treatment indications and are in high-risk scenarios for transmission to others, AASLD suggests a shared decision-making approach with the individual regarding use of antiviral treatment to reduce transmission to others.

**PICO Question 3: Should individuals in the immune-tolerant phase start antiviral therapy versus observation?**

**Population:** Persons who are HBsAg-positive, HBeAg-positive without cirrhosis with HBV DNA > 10,000,000 IU/mL with normal ALT

**Intervention:** Antiviral therapy

**Comparator:** Monitoring or no therapy

**Outcome:** Hepatocellular carcinoma

**Recommendation 3:**

For persons in the immune-tolerant phase (defined as HBeAg-positive, HBV DNA > 10<sup>7</sup> IU/mL, and normal ALT levels), AASLD suggests antiviral therapy for those over age 40 years or with significant liver inflammation (grade 2 or higher) or fibrosis (F2 or greater) on liver biopsy or non-invasive tests. For persons under age 40 years who are interested in starting treatment earlier, AASLD suggests shared decision-making with consideration of risk factors as well as the benefits and risks of treatment.

*Strength of Recommendation: Conditional*

*Quality and Certainty of Evidence: Very low*

**Implementation considerations**

- Accurate identification of immune-tolerant phase requires persistently normal ALT levels with HBV DNA > 10<sup>7</sup> IU/mL in HBeAg-positive persons. Upper limits of normal ALT levels are 35 U/L for males and 25 U/L for females based on ≥2 measurements


≥ 6 months apart. HBeAg-positive individuals with ALT above ULN or with HBV DNA levels < 10<sup>7</sup> IU/mL may be transitioning to immune active CHB and are not the focus of this recommendation.

- Non-invasive tests of fibrosis, such as hepatic transient elastography or serum markers such as FIB-4 can be considered for fibrosis assessment, with elastography showing better performance than FIB-4. A vibration-controlled transient elastography cut-off of 8 kPa yielded a sensitivity of 87% and a specificity of 83% for identifying F2 or higher fibrosis.<sup>[46]</sup>
- For persons younger than 40 years or without significant inflammation or fibrosis, factors to guide decision making should include age (child/adolescent versus adult), family history of HCC, likelihood of adherence to treatment and monitoring, and prevention of transmission to others. As the duration of therapy is anticipated to be many years, addressing the need for long-term adherence and monitoring is important and particularly relevant for children and adolescents being considered for antiviral therapy.
- Close monitoring is recommended if antiviral treatment is not initiated. HBV DNA and ALT levels should be tested at least every 6 months for adolescents and adults with immune-tolerant CHB to monitor for transition to immune-active CHB. A similar monitoring schedule is suggested for children, though the optimal interval has not been determined.

**Background**

In persons who acquire HBV infection at birth or in infancy, most begin life in the immune-tolerant phase of CHB (Table 1),<sup>[47]</sup> characterized by HBeAg-positivity and very high HBV DNA levels > 10<sup>7</sup> IU/mL, but persistently normal ALT levels and minimal or no hepatic inflammation or fibrosis on liver biopsy.<sup>[1]</sup> Although some have questioned whether the immune system is truly tolerant to HBV, the name reflects, that despite persistently high levels of replication for years, overt inflammation and fibrosis do not occur in most individuals. However, the strong association between HBV DNA level and HCC risk has raised the question of whether treatment should be considered during the immune-tolerant phase.<sup>[48–51]</sup>

Transition from the immune-tolerant to immune active phase of CHB may occur in childhood, adolescence, or adulthood, with the average age of transition around 30 years.<sup>[52,53]</sup> Age over 40 years is associated with higher likelihood of significant histological disease in HBeAg-positive persons with normal ALT and late HBeAg seroconversion (beyond age 40) has been associated with an increased risk of HCC.<sup>[51,52,54]</sup> Young individuals who remain consistently in the immune-tolerant phase have a low risk of disease progression or HCC but those with falling HBV DNA levels and rising ALT are likely transitioning from the immune-tolerant to



**FIGURE 2** Management Algorithm for Persons without Cirrhosis who are HBsAg-positive and HBeAg-positive. For persons without cirrhosis who are HBeAg-positive, the decision to initiate antiviral therapy depends on HBV DNA and ALT levels. An upper limit of normal for ALT of 35 U/L for males and 25 U/L for females is recommended to guide management decisions. Those who meet criteria for immune active CHB are recommended for treatment. Those meeting the strict definition of immune-tolerant are generally not recommended for treatment unless older (≥40 years), have significant fibrosis (≥F2) or have another reason for treatment (e.g., prevention of transmission), and those in the indeterminate phase warrant a shared-decision making approach with consideration of potential risks and benefits. Individuals who are HBeAg-positive with HBV DNA levels <20,000 IU/mL are extremely rare, but the treatment approach would be the same as those with HBV DNA ≥20,000 IU/mL. Abbreviations: ALT, alanine aminotransferase; NIT, non-invasive testing; ULN, upper limit of normal.

the immune active phase.<sup>[55,56]</sup> The natural history and impact of therapy in those who fall between the definitions of immune-tolerant and immune active (HBV DNA <10<sup>7</sup> IU/mL and/or ALT 1-2x ULN) phases, the HBeAg-positive indeterminate phase (Figure 2), are less well defined.<sup>[1]</sup>

## Evidence and rationale

Antiviral therapy with NA suppresses HBV DNA replication, although due to very high levels of replication seen during the immune-tolerant phase, HBV DNA levels may not be suppressed to undetectable levels, even with long-term therapy. Studies have largely compared different antiviral strategies rather than treatment versus no treatment (or placebo), with a focus on virological rather than clinical outcomes. Consequently, the impact of treatment during the immune-tolerant phase on cirrhosis and HCC risk is unknown.

The systematic review of studies evaluating treatment in the immune-tolerant phase included 16 studies,<sup>[53,57-69]</sup> of which 9 were comparative (including 4 RCTs) and 4 were in children. The comparative studies evaluated NA vs interferon, NA versus NA combination or NA + interferon versus no treatment. The other 7 studies (3 pediatric) were single-arm observational studies of NA +/- interferon. Based on the systematic review, treatment with NA with peginterferon for 1-1.5 years was associated with a significant

decrease in HBV DNA but had limited effect on HBeAg and HBsAg loss/seroconversion. In an adult study of 4 years of TDF alone vs. TDF plus emtricitabine, combination therapy increased suppression of HBV DNA to <69 IU/mL (OR 2.60 95% CI 1.21, 5.56) but did not improve HBeAg or HBsAg loss.<sup>[68]</sup> Notably, by 4 years of treatment, only 55% in the TDF alone arm achieved HBV DNA <69 IU/mL compared to 76% in the TDF plus emtricitabine arm.

Only one retrospective study of NA therapy for up to 80 months that used propensity score matching reported on HCC incidence or mortality with a HR for HCC of 0.23 (95% CI 0.05, 1.104) and HR for mortality of 0.24 (95% CI 0.066, 0.83).<sup>[70]</sup> Indirect evidence that may support treatment of older persons in the immune-tolerant phase comes from a Korean study showing that treated individuals in the immune active phase of CHB had lower rates of HCC than those untreated in the immune-tolerant phase, though 26% of those in the immune-tolerant group had HBV DNA levels <10<sup>7</sup> IU/mL.<sup>[55]</sup> Individuals who continued to meet all criteria for immune-tolerant disease (HBeAg-positive, ALT <ULN and HBV DNA >10<sup>7</sup> IU/mL) had a very low risk of HCC.<sup>[56,71,72]</sup> Persons who are older, male, with lower HBV DNA levels, higher ALT, and lower platelet count were reported to have a higher risk of HCC but they may be more likely to be transitioning out of the immune-tolerant phase. These data reinforce that serial follow-up is essential to identify transition out of the immune-tolerant phase.

Antiviral therapy may decrease HCC risk by suppressing viral replication, thereby decreasing clonal expansion and integration of HBV DNA into the host genome.<sup>[73,74]</sup> No direct evidence has shown a lower risk of HCC or mortality in persons in the immune-tolerant phase with HBV DNA levels  $>10^7$  IU/mL treated with antiviral therapy. Because subclinical liver injury is associated with an increased HCC risk and is more commonly reported in persons above age 40 in the immune-tolerant phase, the benefit of treatment in older individuals and those with significant fibrosis (F2 or greater) likely outweighs the risks.

Although the potential benefits of treatment in the immune-tolerant phase are uncertain, if treatment reduces the incidence of HCC, the benefits may be substantial. Other considerations may include treatment duration (long-term treatment likely required with non-negligible cost and monitoring burden), adverse events (overall low), risk of resistance mutations (low with ETV and TDF/TAF but may be increased due to very high replication levels in immune-tolerant phase), need for monitoring if treatment is not initiated and transmission risk to personal contacts (limited data). Transition from the immune-tolerant to immune active phase of CHB is usually asymptomatic. Therefore, individuals in the immune-tolerant phase not on antiviral therapy require regular laboratory testing to assess transition to the immune active phase of CHB.

**PICO Question 4: Should HBsAg-positive, HBeAg-negative individuals without cirrhosis and in the indeterminate phase start antiviral therapy versus observation?**

**Population:** Persons who are HBsAg-positive, HBeAg-negative without cirrhosis in indeterminate phase

**Intervention:** Antiviral therapy

**Alternative:** Monitoring without therapy

**Outcome:** Hepatocellular carcinoma or cirrhosis

**Recommendation 4:**

In adults with HBsAg-positive, HBeAg-negative chronic HBV infection without cirrhosis and in the indeterminate phase, AASLD suggests antiviral therapy using a shared decision-making approach by assessing risks and benefits and to reevaluate that decision at each follow-up visit if treatment has not been initiated.

*Strength of recommendation: Conditional*

*Certainty of evidence: Very low*

**Implementation considerations (Figure 3)**

- Factors relevant to decision-making are stage of fibrosis, age, and sex. For example, those who are

older ( $>40$  years), male, and with low normal platelet counts ( $<180$  k/mm<sup>3</sup>) may be more likely to benefit from treatment. Persons with advanced fibrosis (F3/F4) are recommended for treatment. The non-invasive tests thresholds with high sensitivity for advanced fibrosis are FIB-4 of  $>1.45$  and vibration-controlled elastography of  $\geq 8$  kPa. Other factors to consider in shared decision making include pill burden, cost of therapy (although ETV and TDF are generic) and the requirement for regular monitoring.

- If treatment is not initiated, individuals should be monitored with ALT and HBV DNA testing every 3-6 months for the first year and every 6 months thereafter.
- The decision regarding initiation of treatment should be re-assessed at each follow-up visit as preferences and values may change over time. Progression to advanced fibrosis/cirrhosis, or transition to the HBeAg-negative immune active phase should prompt initiation of treatment.
- Individuals with persistently elevated ALT but HBV DNA  $<2000$  IU/mL should be evaluated for other etiologies of liver injury and managed for those etiologies if found.


**Background**

Previous guidance did not recommend treatment of those in the HBeAg-negative indeterminate phase (Table 1).<sup>[1]</sup> Instead, it recommended that such individuals be monitored and have treatment initiated if they transitioned to an immune active phase. In addition, prior guidance suggested that treatment should be initiated if there is evidence of significant fibrosis ( $\geq F2$ ) or moderate inflammation ( $\geq A3/Grade 3$ ) or persistently elevated ALT ( $>ULN$ ) with HBV DNA  $\geq 2000$  IU/mL, especially if over the age of 40 years.<sup>[1]</sup>

Individuals who are HBeAg-negative and in the indeterminate phase are predominantly comprised of two subgroups: (I) those with normal ( $<ULN$ ) or mildly elevated ( $<2XULN$ ) ALT but HBV DNA  $\geq 2000$  IU/mL, and (II) those with elevated ALT ( $>ULN$ ) but HBV DNA  $<2000$  IU/mL. Since fluctuations in ALT and HBV DNA levels may occur during the course of CHB, phase determination should be based on results of ALT and HBV DNA tests on  $\geq 2$  occasions over a 6-to-12-month period. While some individuals in the indeterminate phase may transition to an immune active or an inactive phase, many remain in the indeterminate phase for years. Several cohort studies suggest that individuals who remain in the indeterminate phase are at risk of HCC.<sup>[3,75]</sup>

**Evidence and rationale**

HBsAg-positive, HBeAg-negative adults without evidence of cirrhosis in the indeterminate phase are at risk of



hepatitis flares, cirrhosis, hepatic decompensation, and HCC though the range in risk is wide.<sup>[76]</sup> Studies show that antiviral treatment can decrease these risks in those persons who meet existing indications for treatment,<sup>[77,78]</sup> although the impact on HCC development is small compared to other outcomes such as hepatic decompensation and liver-related mortality.<sup>[79]</sup> Thus, the potential benefit of antiviral therapy in persons who are HBsAg-positive, HBeAg-negative without evidence of cirrhosis and are in the indeterminate phase, in reducing the risk of adverse clinical outcomes, particularly HCC, are expected to be smaller and must be balanced against the need for long-term and often lifelong treatment. Data from a recently published systematic review and meta-analysis<sup>[76]</sup> were leveraged to address the benefits versus harms of initiating antiviral therapy compared to monitoring among HBeAg-negative adults without cirrhosis in the indeterminate phase.

The systematic review for the incidence of HCC in persons in the indeterminate phase included 37 cohorts (9 with and 28 without antiviral therapy) from 32 studies (1 RCT and 31 observational – 6 prospective, 1 retrospective/prospective and 24 retrospective) involving 14,691 individuals.<sup>[76]</sup> The analysis included 4

studies of HBsAg-positive adults who were exclusively HBeAg-positive, 14 with exclusively HBeAg-negative, and 14 with a mix of HBeAg-positive and HBeAg-negative. The pooled annual incidence rate of HCC was 0.32% (95%CI 0.21%-0.48%) overall, 0.24% (95%CI 0.08-0.70%) in those treated and 0.34% (95%CI 0.22-0.53%) in those untreated. On multivariate models, older age, percentage male, positive HBeAg status, and retrospective study design were associated with a higher incidence of HCC, while use of antiviral treatment, higher platelet count, and better study quality were associated with a lower incidence of HCC. The significant association between use of antiviral treatment and lower incidence of HCC (aIRR 0.36, 95%CI 0.16-0.81) persisted after adjusting for age, sex, HBeAg status, and platelet count. There were fewer studies on incident cirrhosis (13 cohorts) and hepatic decompensation (10 cohorts) precluding assessment of the impact of antiviral therapy on these outcomes.

Of the 14 cohorts (2 treated and 12 untreated) that included only adults who were HBeAg-negative, the annual incidence rate of HCC was 0.13% (95%CI 0.01-0.34) overall, 0% in treated and 0.17% (95%CI 0.01-0.43%) in untreated persons.<sup>[80]</sup> There were too few

events for meaningful comparisons between those treated versus untreated.

These data suggest that antiviral treatment may decrease the risk of HCC among adults with CHB who are HBeAg-negative without cirrhosis and in the indeterminate phase; however, the strength of the evidence is low because of cross-comparisons across observational studies, a wide range in risk of HCC overall, and a wide range in benefit. Thus, AASLD suggests that the decision to start antiviral treatment should be individualized, with each person discussing the risks and benefits with their provider.

While NA treatment is safe and available as generics in most countries, the need for long-term and in many cases, lifelong treatment can be a burden to individuals and a financial burden to healthcare systems given that those in the HBeAg-negative indeterminate phase comprises up to 40% of persons with CHB.<sup>[2,3]</sup> The alternative strategy of close monitoring and initiation of antiviral therapy once the individual has transitioned to immune active CHB has been shown to be associated with very low risk of HCC in a large prospective North American study.<sup>[81]</sup> This strategy requires adherence to monitoring but starting treatment in the indeterminate phase also requires adherence to monitoring on treatment.

**PICO Question 5: Should HBsAg-positive individuals without cirrhosis who have been on nucleos(t)ide analogue therapy for at least 3 years and who are HBeAg-negative with undetectable HBV DNA remain on or discontinue therapy?**

**Population:** HBsAg-positive, HBeAg-negative, HBV DNA undetectable for at least 2 years, after at least 3 years of NA therapy, and no cirrhosis

**Intervention:** Stop NA therapy

**Comparator:** Continue NA therapy

**Outcomes:** (a) HBsAg loss; (b) Clinical relapse defined as HBV DNA  $\geq 2000$  and ALT  $> 2x$  ULN; (c) Resumption of antiviral treatment

#### Recommendation 5:

In adults with chronic hepatitis B, who are HBeAg-negative without cirrhosis, with sustained undetectable HBV DNA on nucleos(t)ide analogue therapy, AASLD suggests not withdrawing nucleos(t)ide analogue therapy until HBsAg loss.

*Strength of recommendation: Conditional*

*Certainty of evidence: Very Low*

#### Implementation Considerations (Table 3)

- Persons who have a desire to discontinue therapy should engage in a shared decision-making process with their providers considering the benefits (HBsAg

loss) and risks (hepatitis flare, liver decompensation and need for re-treatment) and need for frequent monitoring.

- Those who may consider stopping treatment should meet all the following criteria:
  - no history of advanced fibrosis/cirrhosis, hepatic decompensation (variceal bleed, ascites, hepatic encephalopathy, hepatorenal syndrome), HCC or extrahepatic complications of HBV.
  - if HBeAg-positive at start of antiviral therapy, have seroconverted to HBeAg-negative and anti-HBe-positive for  $\geq 1$  year and have undetectable HBV DNA maintained for at least 2 years.
  - If HBeAg-negative at start of antiviral therapy, the duration of undetectable HBV DNA should be at least 2 years.
  - have no co-infection with human immunodeficiency virus (HIV) or hepatitis D virus (HDV).
  - have a quantitative HBsAg level  $< 100$  IU/mL.
  - be willing to adhere to frequent monitoring after stopping treatment.
- Following withdrawal of treatment, serum ALT and HBV DNA should be monitored every 1-3 months for the initial 6 months, then every 3 months for the next 6 to 12 months. Thereafter, monitor at 3 to 6 month intervals depending on the ALT and HBV DNA values.
- Treatment should be re-started immediately if any of the following criteria are met:
  - an HBV DNA level  $\geq 10,000$  IU/mL ( $\geq 4$  log IU/mL) regardless of ALT level, or
  - ALT  $\geq 5 \times$  ULN regardless of HBV DNA or
  - total bilirubin  $> 2.5$  mg/dL, or
  - any symptoms of hepatic decompensation.
- Treatment may also be re-started anytime for any of the following reasons: personal wish to re-start, extrahepatic complications of HBV, or if treatment initiation criteria are met (HBV DNA  $\geq 2000$  IU/mL and ALT  $\geq 2x$  ULN).

#### Background

Annual rates of spontaneous and on-treatment NA-related HBsAg loss remain very low ( $\sim 0.5$ -1%).<sup>[22,82]</sup> A small uncontrolled cohort study reported a remarkably high rate of HBsAg loss of 39% at four years, following withdrawal of NA (adefovir) therapy.<sup>[83]</sup> Subsequently, several prospective randomized and retrospective cohort studies have reported variable rates of HBsAg loss ranging from 2-20% over follow-up of up to three years after NA discontinuation.<sup>[84-88]</sup> These findings led the Asian Pacific Association for the Study of Liver and European Association for the Study of the Liver to recommend consideration of withdrawal of NA therapy as a strategy to

**TABLE 3** Approach to individual with desire to discontinue nucleos(t)ide analogue therapy.

Persons who have a strong desire to discontinue therapy should engage in a shared decision-making process with their providers	
<b>Persons who wish to consider stopping treatment must meet ALL the following criteria</b>	<ul style="list-style-type: none"> <li>No <i>history</i> of cirrhosis, any hepatic decompensation (variceal bleed, ascites, hepatic encephalopathy, hepatorenal syndrome), HCC or extrahepatic complications of HBV</li> <li>HBeAg-negative/anti-HBe positive for a minimum of one year (if HBeAg-positive at start of treatment)</li> <li>HBV DNA undetectable for a minimum of 2 y</li> <li>HBsAg level &lt; 100 IU/mL</li> <li>No co-infection with HIV or HDV</li> <li>Agree to frequent monitoring</li> </ul>
<b>Recommended monitoring schedule after stopping treatment</b>	Monitor HBV DNA and ALT levels every 1-3 mo for the first 6 mo, then every 3 mo for the next 6-12 mo and then every 3-6 mo thereafter.
<b>Criteria for IMMEDIATE re-starting of antiviral therapy – only need to meet ONE criterion</b>	<ul style="list-style-type: none"> <li>HBV DNA level <math>\geq 10,000</math> IU/mL (<math>\geq 10^4</math> IU/mL) at any time (independent of ALT)</li> <li>ALT increase &gt; 5xULN (independent of HBV DNA)</li> <li>Total bilirubin &gt; 2.5 mg/dL</li> <li>Hepatic decompensation</li> </ul>
<b>Other criteria for re-starting treatment</b>	<ul style="list-style-type: none"> <li>Personal desire to re-start</li> <li>Extrahepatic complications of HBV</li> <li>Meets treatment initiation criteria (HBV DNA <math>\geq 2000</math> IU/mL and ALT &gt; 2xULN)</li> </ul>

enhance HBsAg loss in adults with HBeAg-negative CHB who have achieved sustained HBV DNA suppression for at least 2-4 years,<sup>[89,90]</sup> while WHO recommends discontinuation in exceptional circumstances.<sup>[13]</sup> The primary risks related to NA withdrawal are ALT flares and worsening of liver disease, including decompensation. A systematic review was conducted to address the benefits and downsides of stopping versus continuing NA therapy among persons who are HBeAg-negative, who do not have cirrhosis and have been on NA therapy for at least three years with undetectable HBV DNA for at least two years. The analysis also included those who were HBeAg-positive at treatment initiation, who experienced HBeAg seroconversion and completed at least one year of consolidation therapy.

## Evidence and rationale

There is consensus that persons with a history of or current evidence of cirrhosis (clinical or histological), history of decompensation or HCC should not stop therapy, due to an increased risk for hepatitis flare and hepatic decompensation following virological relapse; thus, these persons were excluded from this systematic review.<sup>[91]</sup> The decision to stop antiviral therapy among persons who are HBeAg-negative without cirrhosis with the intended goals of enhancing the rate of HBsAg loss, maintaining off-treatment suppression of HBV DNA (partial cure), and removing the burden of chronic therapy is complex. These potential benefits must be weighed carefully against the risk for virological relapse, which may lead to ALT flares, hepatic decompensation, liver transplantation, death, and need for re-treatment.

The systematic review included 11 studies (4 RCTs and 7 observational studies) involving 1,957 individuals (948 in the discontinuation group and 1,009 in the continuation group).<sup>[92]</sup> The studies spanned multiple geographical regions, including China, Taiwan, Germany, Belgium, Canada, and the USA. All studies predominantly enrolled adults, with ages ranging from 30 to 57 years with the proportion of female participants varying from 14.3% to 42%. In the decision-making process, the committee considered that the majority of the evidence supporting the benefit of stopping therapy was derived from four small prospective RCTs in which the rates of HBsAg loss were modest, 10.6% over two years (versus 0% in those who remained on therapy, RR 12.65 (1.58 to 101.51)) while the downsides, i.e. ALT flares 26.9% (RR 11.63 [0.15 to 891.61]) at two years and retreatment 23% (RR 0.24 [0.07-0.4]) at 1.5 years were substantial.<sup>[84,85,87,88]</sup> Seven uncontrolled retrospective cohort studies from routine practice settings reported even higher rates of adverse complications including decompensation and death.<sup>[93-99]</sup> Collectively, the analyzed studies revealed considerable variability in outcomes leading to a very low certainty of evidence. The evidence from RCTs suggested the rate of HBsAg loss was small (11% at 2 years) but the risks of stopping therapy (ALT flares, 27% at two years, decompensation 0% at 1.5 years and need for re-treatment 42% at 5 years) were moderate. Given the long-term safety of NA treatment and availability of low cost generics and reportedly higher rates of adverse complications including decompensation and death after NA discontinuation, from large cohort studies, the committee recommended against withdrawal of therapy until functional cure was achieved.

Of the biomarkers currently available to predict outcomes in NA withdrawal, quantitative HBsAg at the end of treatment is the best. Lower levels of quantitative HBsAg are associated with higher likelihood of HBsAg loss and lower likelihood of re-treatment.<sup>[100–104]</sup> While there is some heterogeneity in the literature regarding the optimal cut-off to guide the decision to stop NAs, a level of quantitative HBsAg <100 IU/mL is regarded as a conservative value that maximizes likelihood of HBsAg loss and minimizes risk of clinical relapse and need for re-treatment. However, achievement of quantitative HBsAg level <100 IU/mL does not guarantee absence of risk and close monitoring after NA withdrawal is still required.

**PICO Question 6: Should individuals with chronic HBV without cirrhosis who cleared HBsAg and HBsAg-positive persons with HCV, HDV, and/or HIV co-infection receive surveillance for HCC?**

**Population:** Persons with HBV infection who either achieved HBsAg loss or have hepatitis C virus (HCV), hepatitis D virus (HDV), and/or human immunodeficiency virus (HIV) co-infection

**Intervention:** Hepatocellular carcinoma surveillance

**Comparator:** No HCC surveillance

**Outcome:** Early HCC diagnosis

**Recommendations:**

**6.** In persons who achieved HBsAg loss, AASLD suggests continued HCC surveillance for those with cirrhosis, with family history of HCC, men who experienced HBsAg loss after age 40, and women who experienced HBsAg loss after age 50 years.

*Strength of recommendation: Conditional*

*Certainty of evidence: Very Low*

**7.** In persons with HBV-HDV co-infection, AASLD suggests HCC surveillance of adults independent of cirrhosis status. The decision to undertake surveillance in children should be individualized due to the risk of HCC being unknown in this population.

*Strength of recommendation: Conditional*

*Certainty of evidence: Very Low*

**8.** In persons with HBV-HIV co-infection, AASLD suggests HCC surveillance for men  $\geq 18$  years of age and women  $\geq 40$  years of age.

*Strength of recommendation: Conditional*

*Certainty of evidence: Very Low*

**9.** In persons with HBV-HCV co-infection, AASLD recommends treatment for HCV and suggests HCC surveillance as per criteria for HBV mono-infection.

*Strength of recommendation: Conditional*

*Certainty of evidence: Very Low*

## Implementation considerations

- Determination of HCC risk after HBsAg clearance using specific prediction models may be used to aid in decision making for surveillance of intermediate-to-high risk persons but these models require further validation. For those persons for whom the timing of HBsAg loss is unknown, the decision to undertake surveillance should be individualized, with consideration of cirrhosis and family history of HCC.
- Direct acting antiviral (DAA) therapy is recommended for all persons with chronic HCV infection. For those with prior HCV infection (anti-HCV positive, HCV RNA negative), surveillance for HCC is the same as those with HBV alone.
- For persons with HBV-HDV co-infection, AASLD suggests HCC surveillance of adults independent of cirrhosis status. As the risk of HCC among children and adolescents with HDV coinfection is largely unknown, the decision to undertake surveillance should be individualized, with consideration of age, family history and stage of fibrosis.
- For those with prior HDV infection (anti-HDV positive, HDV RNA negative), surveillance for HCC is the same as those with HBV alone.
- For persons with triple or quadruple viral infections (HBV plus HIV, HDV and/or HCV), the surveillance recommendation should be that of the coinfection with the highest associated risk. For example, if HBV-HDV-HCV, the surveillance would follow that for HBV-HDV.
- HCC surveillance with ultrasound and serum AFP performed at semiannual (approximately every 6 mo) intervals is recommended as the most cost-effective approach per the 2023 AASLD HCC guideline.<sup>[105]</sup>

## Background

CHB infection is the most common cause of HCC worldwide.<sup>[106]</sup> HCC can occur in persons with CHB without cirrhosis and in persons who have cleared HBsAg. Prior studies of persons with CHB<sup>[107]</sup> with or without cirrhosis<sup>[108]</sup> have shown that regular HCC surveillance can increase survival. The 2023 AASLD HCC guideline<sup>[105]</sup> recommends HCC surveillance (Table 4) for persons with cirrhosis and those with a higher risk (annual HCC incidence  $\geq 0.2\%$ ).

As HCC risk may differ in those who have achieved HBsAg loss<sup>[109,110]</sup> and those with other viral co-infection,<sup>[111,112]</sup> systematic reviews were performed to obtain HCC risk information for these populations to inform the current guideline.

## Evidence and rationale

For individuals who have cleared HBsAg, one study reported an annual HCC incidence of 0.86% overall,

**TABLE 4** Target groups for hepatocellular carcinoma surveillance.

<b>Chronic HBV infection with cirrhosis<sup>a</sup></b>	Child-Pugh A-B, and transplant-eligible Child-Pugh C
<b>Chronic HBV infection without cirrhosis with increased HCC risk<sup>a</sup></b>	Man from endemic country <sup>b</sup> age > 40 years
	Woman from endemic country <sup>b</sup> age > 50 years
	Person from Africa at earlier age <sup>c</sup>
	Family history of HCC
	PAGE-B score $\geq 10^d$
<b>Co-infection without cirrhosis</b>	HBV/HDV coinfection: all adult persons
	HBV/HIV coinfection: man $\geq 18$ years and woman $\geq 40$ years of age
<b>HBsAg loss with increased risk</b>	All persons with cirrhosis
	Man > 40 years at time of HBsAg loss
	Woman > 50 years at time of HBsAg loss
	Family history of HCC

<sup>a</sup>Recommendations as per the 2023 AASLD HCC Practice Guidance

<sup>b</sup>Endemic country as defined as having  $\geq 2\%$  prevalence chronic HBV infection (most of Africa, Asia, the Middle East, and Eastern Europe; see Polaris Global Distribution maps for most up to date HBsAg prevalence: <https://cdafound.org/polaris/global-distribution>)

<sup>c</sup>Surveillance can be initiated as early as third decade of life given median age 46 years at HCC diagnosis

<sup>d</sup>Other risk calculators (e.g., REACH-B, REAL-B) can be considered. PAGE-B was specifically validated for those who have been on antiviral treatment; REACH-B was validated in untreated individuals.

Abbreviations: HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HDV, hepatitis D virus; HIV, human immunodeficiency virus.

2.42% in those with cirrhosis, 0.43% in those without cirrhosis, 1.07% for males, 0.57% for females, 1.21% if  $\geq 50$  years, and 0.33% if  $< 50$  years,<sup>[113]</sup> while another reported a rate of 0.4% for males and 0% for females without cirrhosis.<sup>[114]</sup> In a meta-analysis of 24 studies of 33,838 persons who cleared HBsAg, the pooled proportions of HCC occurrence ranged from 0.35% to 0.78% per year following treatment-induced or spontaneous HBsAg loss, respectively.<sup>[110]</sup> Another meta-analysis reported higher HCC risk if persons were older (45-50 years) at the time of HBsAg loss.<sup>[109]</sup> Both meta-analyses showed a strong association between male sex and family history of HCC with risk of HCC after HBsAg loss. Taken together, following HBsAg loss whether spontaneous or with antiviral therapy, significant HCC risk remains for those with established cirrhosis and for those without cirrhosis who were 45-50 years or older at the time of HBsAg loss. A recently proposed risk score after HBsAg clearance based on age, presence of cirrhosis, family history of HCC, and moderate alcohol consumption can also be used to consider HCC surveillance for intermediate-to-high risk persons.<sup>[113]</sup>

There are no FDA-approved therapies for HDV and persons with HDV coinfection are at higher risk for progressive liver disease in the absence of effective therapies. For persons with HDV co-infection, a U.S. study of 4817 persons with HBV including 158 with HDV found an HCC incidence per 1,000 person-years of 18.65 in HBV/HDV versus 4.84 in HBV mono-infected individuals.<sup>[115]</sup> The large majority of both mono-infected (92.3%) and co-infected (87.3%) participants in this study did not have cirrhosis. These data suggest that the


annual HCC risk for those with HBV/HDV coinfection is above the cost-effective HCC surveillance threshold (i.e.  $> 0.2\%$ ) even for persons without cirrhosis.<sup>[105]</sup> Natural history data on children and adolescents are sparse<sup>[116]</sup> but HCC has been reported in this age group, leading to the recommendation to individualize the decision to undertake surveillance with consideration of age (e.g. older adolescents), stage of fibrosis (if F2 or higher) or family history of cirrhosis or HCC.

For persons with HBV and HIV co-infection, a U.S. study reported an HCC incidence rate of 2.09 (1.60-2.73) per 1000 person-years in the modern combination antiretroviral therapy era (2006-2015).<sup>[117]</sup> In another analysis inclusive of HBV/HIV individuals from 1995-2016, the incidence rate of HCC per 1000 person-years was 1.8 overall, 1.0 if  $< 40$  years of age, 2.1 if 40-49 years, 2.6 if  $\geq 50$  years, 0.7 for females, 1.8 for males, 3.3 if HBV DNA is detectable and 1.9 if not, suggesting that male sex and age  $\geq 40$  represent higher risk groups who may benefit from HCC surveillance.<sup>[118]</sup>

For persons with HBV and HCV co-infection, the systematic review identified 4 studies that provide HCC incidence, all in the pre-DAA era.<sup>[14,117,119-121]</sup> A large study from Australia including 2604 HBV/HCV co-infected persons with a median age of 35 years reported low HCC incidence per 10,000 person-years of 5.9 overall, 6.52 for males and 3.86 for females.<sup>[119]</sup> The other two studies included few participants ( $< 140$ ) and the fourth study was a systematic review, which reported substantially lower HCC risk with HCV cure among HBV/HCV. DAA therapy is recommended

### AASLD-recommended algorithm for CHB management

A stepwise guide to screening, treatment decisions, and long-term surveillance based on updated AASLD 2025 guidelines




**FIGURE 4** The Centers for Disease Control and Prevention recommends that all adults should be screened for hepatitis B at least once during their lifetime and all pregnant persons during each pregnancy, preferably in the first trimester, regardless of vaccination status or history of testing using a triple panel, (hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), and total antibody to hepatitis B core antigen (anti-HBc)). Persons negative for HBsAg, anti-HBc and anti-HBs should receive HBV vaccination. Persons positive for anti-HBc ± HBsAg may require antiviral prophylaxis in the setting of immunosuppression. Pregnant persons who are found to be HBsAg positive should receive either tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) beginning at gestational week 28 if their viral load is found to be >200,000 IU/mL. Post-delivery, the infant should receive hepatitis B immunoglobulin (HBIG) within 12 hours and HBV vaccination within 24 hours of birth; antiviral treatment can be stopped immediately after delivery if there is no clinical indication for ongoing anti-viral treatment. All HBsAg positive persons should be tested for hepatitis B e antigen (HBeAg), HBV DNA, alanine aminotransferase (ALT) levels and assessed for fibrosis stage non-invasively (FIB-4 or hepatic elastography) or by liver biopsy. If cirrhosis is present, persons should initiate antiviral therapy regardless of HBV DNA or ALT level. For HBeAg positive persons without cirrhosis, antiviral treatment is indicated for an ALT level  $\geq 2 \times$  ULN and HBV DNA


≥20,000 IU/mL. For HBeAg positive persons in the immunetolerant phase (IT) (HBV DNA >10 million IU/ml and normal ALT) treatment should be considered if age over 40 years or there is significant inflammation (≥A2) or fibrosis (≥F2). For HBeAg positive persons in the indeterminate phase (not IT or immune active (IA)) consider treatment using a shared decision approach. For HBeAg positive persons without a treatment indication, monitoring with HBV DNA and ALT every 3-6 months is recommended. For HBeAg negative persons, if cirrhosis is present, treatment should be initiated regardless of HBV DNA or ALT level. For HBeAg negative persons without cirrhosis, treatment is indicated for an ALT level ≥2 X ULN and HBV DNA ≥2,000 IU/mL. For HBeAg negative persons in the indeterminate phase (not inactive or IA) consider treatment using a shared decision approach. For HBeAg negative persons without a treatment indication (inactive disease (HBV DNA <2,000 IU/ml and normal ALT)), monitoring with HBV DNA and ALT every 3-6 months is recommended. For persons who are HBeAg-positive or negative with viremia not meeting disease-specific treatment indications and who are in high-risk scenarios for transmission to others, AASLD suggests a shared decision-making approach regarding antiviral treatment. For persons undergoing monitoring without treatment, the need for antiviral therapy should be reviewed at each follow-up visit. For HBeAg negative persons without cirrhosis on nucleos(t)ide analogues (NA) (including those who started antiviral therapy HBeAg positive and achieved seroconversion to anti-HBe for at least one year) and who have HBV DNA suppression for ≥3 years and a low HBsAg level (<100 IU/mL), consideration can be given to stopping treatment provided the person is willing to adhere to close post-withdrawal monitoring. Treatment should be re-started for an increased in HBV DNA ≥10,000 IU/ml regardless of ALT levels or an increase in ALT level >5x ULN independent of HBV DNA level. An alternate and preferable approach for HBeAg negative persons on NA treatment is to continue treatment until HBsAg loss is achieved and confirmed, after which treatment can be stopped. Hepatocellular carcinoma (HCC) surveillance is recommended for persons with cirrhosis, a family history of HCC, men >40 years and women >50 years from endemic countries and earlier if from African countries, adults co-infected with HDV, and HIV (starting age 18 in men and 40 in women). HCC surveillance should continue after HBsAg loss, if it occurs after age 40 in men and age 50 in women.<sup>[122]</sup> Abbreviations: ALT, alanine aminotransferase; FIB-4, fibrosis-4 index; HBIg, hepatitis B immune globulin; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HIV, human immunodeficiency virus; IA, immune active; LLOQ, lower limit of quantification; TND, target not detected; ULN, upper limit of normal; VCTE, vibration-controlled transient elastography.

for all persons with chronic HCV infection.<sup>[123]</sup> Those with HBV/HCV co-infection are expected to have similar HCC risk after HCV cure to that of HBV

mono-infected persons, highlighting the importance of achieving HCV cure as an important means of reducing HCC risk.



**FIGURE 5** Management of HBsAg-positive Persons with Cirrhosis and/or Decompensated Cirrhosis.<sup>[1]</sup> All HBsAg-positive persons should undergo staging tests to determine if cirrhosis is present. Those with cirrhosis (compensated or decompensated) are recommended for antiviral treatment regardless of the level of HBV DNA or ALT. All require surveillance of HCC and those with decompensated cirrhosis should be referred for consideration of liver transplantation. Abbreviations: ETV, entecavir; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; LSM, liver stiffness measure; NA, nucleos(t)ide analogue; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.



## INTEGRATION OF AASLD 2018 and 2025 GUIDELINES

There are multiple topics well covered in the previous 2018 guidance and for which recommendations have not changed. An integrated treatment algorithm of the new 2025 guidelines and prior 2018 guidelines is provided in [Figure 4](#).

- Treatment of children
- Treatment of HBeAg positive and negative immune active CHB with ALT  $> 2x$  ULN
- Strategies to enhance adherence with long-term therapy
- Treatment of persons with cirrhosis ([Figure 5](#))
- Persons with CHB on NA therapy with intermittent or persistent low-level viremia ([Figure 6](#))
- Persons with evidence of virologic breakthrough ([Figure 6](#))
- Management of CHB in special populations such as those who are transplant recipients (liver and non-liver), those with acute HBV, and those with coinfections (HCV, HDV and HIV).

## LIMITATIONS OF THIS GUIDELINE AND RESEARCH GAPS

1. Most of the guideline recommendations have low or very low certainty of evidence, highlighting the need for higher quality data to aid in refining future recommendations.

2. Nomenclature harmonization was not addressed in this guideline. This would be best addressed through a multi-society consensus process. The key areas include:

- Terminology of the phases of infection/disease in CHB
- Determination of upper limits of normal for ALT for male and female adults and children
- Consensus on terminology of indeterminate versus grey zone to describe the groups with ALT and/or HBV DNA levels outside the phase of immune active and inactive CHB

## Controversial sections and additional topics that are not addressed in the current guideline

Additional areas in the realm of CHB treatment not addressed were:

- Role of HBsAg quantitation, HBV RNA and hepatitis B core-related antigen (HBcrAg) in management of CHB
- Benefit of treatment to prevent HCC among inactive carriers with high HBsAg levels ( $> 1000$  IU/mL)
- Role of peginterferon add-on or switch therapy to NA as strategy to achieve functional cure

- Diagnostic and prognostic performance of NITs as a guide to antiviral treatment initiation
- While the WHO guideline excluded consideration of HBeAg status and used a single threshold (> 2000 IU/mL) for HBV DNA to determine treatment eligibility, the AASLD guideline continues to endorse use of HBeAg and uses additional thresholds for HBV DNA to guide decision-making. This use reflects the ease of access to laboratory testing in the U.S. versus low and middle-income countries and the differences in level of viremia and responses to treatment in persons who are HBeAg-positive versus those who are HBeAg-negative.

## Plans for updating

The topics listed above that were not covered in this guideline will be addressed in future guideline documents and expert practice opinion papers. As the field of HBV therapeutics is robust and new drug therapies focused on functional cure are anticipated, updated guidelines can be anticipated as new therapies are FDA-approved.

## ACKNOWLEDGEMENTS

This research was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the National Institutes of Health (NIH). The contributions of the NIH author(s) are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.

## CONFLICTS OF INTEREST

Calvin Q. Pan consults for Gilead. Anna S. Lok consults for Abbott, Bii Biosciences, Chroma, Enochian, GSK, Grifols, Moderna, Precision, Pfizer, Roche, TARGET, Virion, and Zenasbio. She is on the DSMB for Novo Nordisk. Jordan J. Feld consults for Precision Biosciences, Vir, Roche, GSK, Gilead, Bluejay Therapeutics, AbbVie, Aligos, and Gilead. Arthur Y. Kim consults for Clinical Care Options. He serves on the DSMB for Kintor and Shionogi. Mindie H. Nguyen is on the speakers' bureau for CLDF. Susanna Naggie consults for Pardes. She owns stock in Vir. Mark S. Sulkowski consults for Gilead, Precision Biosciences, Aligos, AbbVie, Virion, Antios, and GK. He is on the DSMB for Gilead. Jacki Chen consults for GSK, Gilead, and Arbutus. He advises the Hepatitis B Foundation, Taiwan Hepatitis Information & Care Association and AASLD. The remaining authors have no conflicts to report.

## ORCID

Marc G. Ghany [ID https://orcid.org/0000-0003-2837-0188](https://orcid.org/0000-0003-2837-0188)  
 Calvin Q. Pan [ID https://orcid.org/0000-0003-2700-9382](https://orcid.org/0000-0003-2700-9382)  
 Anna S. Lok [ID https://orcid.org/0000-0002-5811-6845](https://orcid.org/0000-0002-5811-6845)  
 Jordan J. Feld [ID https://orcid.org/0000-0003-2640-2211](https://orcid.org/0000-0003-2640-2211)  
 Joseph K. Lim [ID https://orcid.org/0000-0003-1126-8128](https://orcid.org/0000-0003-1126-8128)  
 Su H. Wang [ID https://orcid.org/0000-0002-1645-4213](https://orcid.org/0000-0002-1645-4213)  
 Arthur Y. Kim [ID https://orcid.org/0000-0003-4712-2657](https://orcid.org/0000-0003-4712-2657)  
 Amy S. Tang [ID https://orcid.org/0000-0002-8151-2686](https://orcid.org/0000-0002-8151-2686)  
 Mindie H. Nguyen [ID https://orcid.org/0000-0002-6275-4989](https://orcid.org/0000-0002-6275-4989)  
 Susanna Naggie [ID https://orcid.org/0000-0001-7721-6975](https://orcid.org/0000-0001-7721-6975)  
 Mark S. Sulkowski [ID https://orcid.org/0000-0002-2145-6352](https://orcid.org/0000-0002-2145-6352)  
 M. Hassan Murad [ID https://orcid.org/0000-0002-8293-5242](https://orcid.org/0000-0002-8293-5242)  
 Khaled S. Mohammad [ID https://orcid.org/0000-0001-7207-8884](https://orcid.org/0000-0001-7207-8884)  
 Norah A. Terrault [ID https://orcid.org/0000-0003-4143-1950](https://orcid.org/0000-0003-4143-1950)

## REFERENCES

1. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018;67:1560–99.
2. Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, et al. Determination of hepatitis B phenotype using biochemical and serological markers. *J Viral Hepat*. 2017;24:320–9.
3. Huang DQ, Li X, Le MH, Le AK, Yeo YH, Trinh HN, et al. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. *Clin Gastroenterol Hepatol*. 2022;20:1803–812 e1805.
4. Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. *J Viral Hepat*. 2021;28:1025–33.
5. Sterling RK, Duarte-Rojo A, Patel K, Asrani SK, Alsawas M, Dranoff JA, et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. *Hepatology*. 2025;81:672–724.
6. Sterling RK, Patel K, Duarte-Rojo A, Asrani SK, Alsawas M, Dranoff JA, et al. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. *Hepatology*. 2025;81:321–57.
7. Tapper EB, Lok AS. Use of Liver Imaging and Biopsy in Clinical Practice. *N Engl J Med*. 2017;377:756–68.
8. Polaris Observatory C. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. *Lancet Gastroenterol Hepatol*. 2023;8:879–907.
9. Bixler D, Barker L, Lewis K, Peretz L, Teshale E. Prevalence and awareness of Hepatitis B virus infection in the United

- States: January 2017 - March 2020. *Hepatol Commun*. 2023;7:e0118.
10. Razavi-Shearer D, Gamkrelidze I, Pan CQ, Razavi-Shearer K, Blach S, Estes C, et al. The impact of immigration on hepatitis B burden in the United States: a modelling study. *Lancet Reg Health Am*. 2023;22:100516.
  11. Pham TTH, Toy M, Hutton D, Thompson W, Connors EE, Nelson NP, et al. Gaps and Disparities in Chronic Hepatitis B Monitoring and Treatment in the United States, 2016-2019. *Med Care*. 2023;61:247-53.
  12. Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. *J Hepatol*. 2022;76:63-74.
  13. WHO. Accessed December 19, 2024. <https://iris.who.int/bitstream/handle/10665/376353/9789240090903-eng.pdf?sequence=1>
  14. Pan CQ, Saadi S, Ghany MG, Feld JJ, Lim JK, Kim A, et al. Technical systematic review supporting 2025 AASLD practice guidelines on management of chronic hepatitis B. *Hepatology*. 2025. Online ahead of print. doi: 10.1097/HEP.0000000000001584
  15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336:924-6.
  16. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. *J Clin Epidemiol*. 2011;64:1311-6.
  17. Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. *BMJ*. 2016;353:i2016.
  18. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol*. 2013;66:719-25.
  19. Connors EE, Panagiotakopoulos L, Hofmeister MG, Spradling PR, Hagan LM, Harris AM, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. *MMWR Recomm Rep*. 2023;72:1-25.
  20. Force USPST Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening for Hepatitis B Virus Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2019;322:349-54.
  21. Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. *Lancet Infect Dis*. 2021;21:70-84.
  22. Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. *Lancet Gastroenterol Hepatol*. 2019;4:227-38.
  23. Pan X, Chen J, Zhou L, Ou X, He F, Liu Y, et al. Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus. *Sci Rep*. 2020;10:13631.
  24. Pan CQ, Zhu L, Yu AS, Zhao Y, Zhu B, Dai E. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis. *Clin Infect Dis*. 2024;79:953-64.
  25. Pan CQ, Dai E, Duan Z, Han G, Zhao W, Wang Y, et al. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China. *Gut*. 2022;71:798-806.
  26. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. *N Engl J Med*. 2016;374:2324-34.
  27. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. *Hepatology*. 2014;60:468-76.
  28. APR. Antiviral Pregnancy Registry Interim report - January 1st, 1989 through July 31, 2023; Issued in December 2023. Available at the Website. Accessed February, 2024. <http://www.apregistry.com>
  29. Pan CQ, Dai E, Mo Z, Zhang H, Zheng TQ, Wang Y, et al. Tenofovir and Hepatitis B Virus Transmission During Pregnancy: A Randomized Clinical Trial. *JAMA*. 2025;333:390-9.
  30. Yi W, Pan CQ, Hao J, Hu Y, Liu M, Li L, et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. *J Hepatol*. 2014;60:523-9.
  31. Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. *Arch Pediatr Adolesc Med*. 2011;165:837-46.
  32. Xiao F, Lan A, Mo W. Breastfeeding from mothers carrying HBV would not increase the risk of HBV infection in infants after proper immunoprophylaxis. *Minerva Pediatr*. 2020;72:109-15.
  33. Kayes T, Crane H, Symonds A, Dumond J, Cottrell M, Di Girolamo J, et al. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. *Aliment Pharmacol Ther*. 2022;56:510-8.
  34. Hu X, Wang L, Xu F. Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage. *Int J Infect Dis*. 2019;87:8-12.
  35. Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. *Sci Rep*. 2016;6:27251.
  36. Henderson DK, Dembry L, Fishman NO, Grady C, Lundstrom T, Palmore TN, et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. *Infect Control Hosp Epidemiol*. 2010;31:203-32.
  37. CDC. Hepatitis B Surveillance [Internet]. 2022 Viral Hepatitis Surveillance Report. 2024. Accessed January 30, 2025. <https://www.cdc.gov/hepatitis-surveillance-2022/hepatitis-b/index.html>
  38. Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL, et al. Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71:477-83.
  39. Lu PJ, Hung MC, Srivastava A, Grohskopf LA, Kobayashi M, Harris AM, et al. Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. *MMWR Surveill Summ*. 2021;70:1-26.
  40. Henderson DK, Dembry L-M, Sifri CD, Palmore TN, Dellinger EP, Yokoe DS, et al. Management of healthcare personnel living with hepatitis B, hepatitis C, or human immunodeficiency virus in US healthcare institutions. *Infection Control & Hospital Epidemiology*. 2022;2022:147-55.
  41. van der Eijk AA, de Man RA, Niesters HG, Schalm SW, Zaaijer HL. Hepatitis B virus (HBV) DNA levels and the management of HBV-infected health care workers. *J Viral Hepat*. 2006;13:2-4.
  42. Gatanaga H, Hayashida T, Tanuma J, Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. *Clin Infect Dis*. 2013;56:1812-9.
  43. Heuft MM, Houba SM, van den Berk GE, Smitsaert van de Haere T, van Dam AP, Dijkstra LM, et al. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. *AIDS*. 2014;28:999-1005.
  44. Shilaih M, Marzel A, Scherrer AU, Braun DL, Kovari H, Rougemont M, et al. Dually Active HIV/HBV Antiretrovirals as

- Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. *J Infect Dis.* 2016;214:599–606.
45. Mizushima D, Takano M, Aoki T, Ando N, Uemura H, Yanagawa Y, et al. Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men. *Hepatology.* 2023;77:2084–92.
  46. Duarte-Rojo A, Taouli B, Leung DH, Levine D, Nayfeh T, Hasan B, et al. Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. *Hepatology.* 2025;81:725–48.
  47. Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. *Cell Mol Immunol.* 2015;12:258–63.
  48. Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? *Clin Gastroenterol Hepatol.* 2021;19:2006–14.
  49. Jeng WJ, Wong GL. The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? *Hepatol Commun.* 2023;7:e0060.
  50. Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. *Viruses.* 2017;9:96.
  51. Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. *J Gastroenterol.* 2020;55:383–9.
  52. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. *Hepatology.* 2010;51:435–44.
  53. Feld JJ, King WC, Ghany MG, Chang KM, Terrault N, Perrillo RP, et al. Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. *Clin Gastroenterol Hepatol.* 2023;21:1503–512 e1504.
  54. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. *Clin Gastroenterol Hepatol.* 2009;7:227–33.
  55. Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. *Gut.* 2018;67:945–52.
  56. Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. *Aliment Pharmacol Ther.* 2020;52:196–204.
  57. Lal BB, Sood V, Khanna R, Rawat D, Verma S, Alam S. Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B—First study in children. *Indian J Gastroenterol.* 2018;37:326–34.
  58. Liu N, Yang N, Ma W, Yang S, Hu C, Li J, et al. Efficacy of Antiviral Treatment in Liver Biopsy-Proven Immune-Tolerant Chronic Hepatitis B Patients: A Retrospective Cohort Study. *Front Med (Lausanne).* 2021;8:655530.
  59. Marrone A, Zampino R, Portella G, Grimaldi M, Durante-Mangoni E, Santarpia L, et al. Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B. *J Viral Hepat.* 2005;12:186–91.
  60. Mehr MT, Khan H, Ul Iman N. Telbivudine monotherapy in the treatment of hbeag positive chronic hepatitis B infection with normal baseline ALT levels. *Journal of Postgraduate Medical Institute.* 2013;27:38–41.
  61. Mieli-Vergani G, Bansal S, Daniel JF, Kansu A, Kelly D, Martin C, et al. Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B. *J Pediatr Gastroenterol Nutr.* 2021;73:156–60.
  62. Poddar U, Yachha SK, Agarwal J, Krishnani N. Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon? *J Viral Hepat.* 2013;20:311–6.
  63. Qian J, Zhang C, Liu H, Wang G, Zhao H. Serum HBV RNA as a predictor of virological response in treatment-naive chronic HBeAg-positive HBV-infected patients with normal alanine aminotransferase. *Chin Med J (Engl).* 2022;135:2351–3.
  64. Rosenthal P, Ling SC, Belle SH, Murray KF, Rodriguez-Baez N, Schwarzenberg SJ, et al. Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection. *Hepatology.* 2019;69:2326–37.
  65. Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT\*. *J Viral Hepat.* 2004;11:552–8.
  66. Yalcin K, Degertekin H, Kokoglu OF, Ayaz C. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels. *Turk J Gastroenterol.* 2004;15:14–20.
  67. Zhu S, Zhang H, Dong Y, Wang L, Xu Z, Liu W, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. *J Hepatol.* 2018;68:1123–8.
  68. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. *Gastroenterology.* 2014;146:1240–8.
  69. D'Antiga L, Aw M, Atkins M, Moorat A, Vergani D, Mieli-Vergani G. Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study. *J Pediatr.* 2006;148:228–33.
  70. Chang Y, Choe WH, Sinn DH, Lee JH, Ahn SH, Lee H, et al. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. *J Infect Dis.* 2017;216:1407–14.
  71. Lee HW, Chon YE, Kim BK, Yip TC, Tse YK, Wong GL, et al. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. *Eur J Intern Med.* 2021;84:68–73.
  72. Jeon MY, Kim BK, Lee JS, Lee HW, Park JY, Kim DY, et al. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. *Clin Mol Hepatol.* 2021;27:295–304.
  73. Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, et al. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. *Gastroenterology.* 2016;151:986–998 e984.
  74. Chow N, Wong D, Lai CL, Mak LY, Fung J, Ma HT, et al. Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion. *Clin Infect Dis.* 2023;76:e801–9.
  75. Liu M, Zhao T, Zhang Y, Zhang AM, Geng J, Xia X. The incidence of hepatocellular carcinoma and clearance of hepatitis B surface for CHB patients in the indeterminate phase: a systematic review and meta-analysis. *Front Cell Infect Microbiol.* 2023;13:1226755.
  76. Lai JC, Wong GL, Tse YK, Hui VW, Lai MS, Chan HL, et al. Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis. *J Hepatol.* 2025;82:992–1003; 2024.
  77. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, American Association for the Study of Liver D. AASLD guidelines for treatment of chronic hepatitis B. *Hepatology.* 2016;63:261–83.
  78. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases

- after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. *Hepatology*. 2017;66:1444–53.
79. Yip TC, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. *J Hepatol*. 2019;70:361–70.
  80. Yip T WGSaftsrbLJ, et al *J Hepatol* 2024.
  81. Lok AS, Perrillo R, Lalama CM, Fried MW, Belle SH, Ghany MG, et al. Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. *Hepatology*. 2021;73:2124–40.
  82. Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. *Gastroenterology*. 2019;156:635–646 e639.
  83. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. *Gastroenterology*. 2012;143:629–636 e621.
  84. van Bommel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, et al. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. *J Hepatol*. 2023;78:926–36.
  85. Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). *Gut*. 2019;68:2206–13.
  86. Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. *Hepatology*. 2018;68:425–34.
  87. Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. *J Hepatol*. 2017;67:918–24.
  88. Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF. Rebound of HBV DNA after cessation of nucleos(t)ide analogues in chronic hepatitis B patients with undetectable covalently closed. *JHEP Rep*. 2020;2:100112.
  89. European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2025.
  90. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int*. 2016;10:1–98.
  91. Hsu YC, Wu JL, Tseng CH, Nguyen MH, Lin CW, Hung CL. Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice. *Clin Gastroenterol Hepatol*. 2022;20:1413–15 e1413.
  92. Pan Cea. Sytematic Review. *Hepatology* 2025;x:xx.
  93. Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou A, Yang HC, et al. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. *Liver Int*. 2022;42:541–50.
  94. Chen CH, Hu TH, Wang JH, Lai HC, Hung CH, Lu SN, et al. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. *Hepatol Int*. 2020;14:317–25.
  95. Chen CH, Hung CH, Wang JH, Lu SN, Lai HC, Hu TH, et al. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. *J Infect Dis*. 2019;219:1624–33.
  96. Van Hees S, Bourgeois S, Van Vlierberghe H, Serste T, Francque S, Michielsen P, et al. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. *Aliment Pharmacol Ther*. 2018;47:1170–80.
  97. Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. *J Clin Gastroenterol*. 2012;46:865–70.
  98. Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. *Am J Gastroenterol*. 2009;104:1940–6; quiz 1947.
  99. Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, et al. Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment. *Intervirology*. 2005;48:174–82.
  100. Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, et al. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). *Gastroenterology*. 2022;162:757–771 e754.
  101. Hsu YC, Mo LR, Chang CY, Wu MS, Kao JH, Wang WL, et al. Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients. *Clin Gastroenterol Hepatol*. 2016;14:1490–98 e1493.
  102. Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, et al. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. *Clin Gastroenterol Hepatol*. 2015;13:1984–992 e1981.
  103. Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. *J Hepatol*. 2014;61:515–22.
  104. Wang CC, Tseng KC, Hsieh TY, Tseng TC, Lin HH, Kao JH. Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg. *Am J Gastroenterol*. 2016;111:1286–94.
  105. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology*. 2023;78:1922–65.
  106. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology*. 2012;142:1264–273 e1261.
  107. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol*. 2004;130:417–22.
  108. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. *PLoS Med*. 2014;11:e1001624.
  109. Liu F, Wang XW, Chen L, Hu P, Ren H, Hu HD. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. *Aliment Pharmacol Ther*. 2016;43:1253–61.
  110. Vittal A, Sharma D, Hu A, Majeed NA, Terry N, Auh S, et al. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. *Aliment Pharmacol Ther*. 2022;55:8–25.
  111. Chang TE, Su CW, Huang YS, Huang YH, Hou MC, Wu JC. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. *J Chin Med Assoc*. 2022;85:30–41.
  112. Kamal H, Fornes R, Simin J, Stal P, Duberg AS, Brusselsaers N, et al. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. *J Viral Hepat*. 2021;28:1431–42.
  113. Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, et al. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. *J Hepatol*. 2022;77:632–41.

114. Kim GA, Lee HC, Kim MJ, Ha Y, Park EJ, An J, et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. *J Hepatol*. 2015;62:1092–9.
115. John BV, Bastaich D, Amoli MM, Wong RJ, Evon DM, Rogal SS, et al. Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort. *Hepatology*. 2024.
116. Alfaiate D, Clement S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. *J Hepatol*. 2020;73:533–9.
117. Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, et al. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. *JAMA Netw Open*. 2021;4:e2037512.
118. Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, et al. Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. *Hepatology*. 2021;74:1190–202.
119. Amin J, Dore GJ, O'Connell DL, Bartlett M, Tracey E, Kaldor JM, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. *J Hepatol*. 2006;45:197–203.
120. Oh JK, Shin HR, Lim MK, Cho H, Kim DI, Jee Y, et al. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. *BMC Cancer*. 2012;12:452.
121. Awadh AA, Alharthi AA, Alghamdi BA, Alghamdi ST, Baqays MK, Binrabaa IS, et al. Coinfection of Hepatitis B and C Viruses and Risk of Hepatocellular Carcinoma: Systematic Review and Meta-analysis. *J Glob Infect Dis*. 2024;16:127–34.
122. Updated AASLD Guidelines for Chronic Hepatitis B Treatment. *Hepatology*. 2025. Online ahead of print. 10.1097/HEP.0000000000001607
123. Bhattacharya D, Aronsohn A, Price J, Lo Re V, Panel A-IHG. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Clin Infect Dis*. 2023.

**How to cite this article:** Ghany MG, Pan CQ, Lok AS, Feld JJ, Lim JK, Wang SH, et al. AASLD IDSA Practice Guideline on treatment of chronic hepatitis B. *Hepatology*. 2026;83:974–997.  
<https://doi.org/10.1097/HEP.0000000000001549>